News
Media
Conference
Publications
Resources
Partners
Subscribe

Spotlight -

Geographic Atrophy

Opinion|Videos|February 14, 2025

Perspectives on the Usefulness of Real-world Data

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Episodes in this series

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP. 2 Advantages of the molecular structure of aflibercept

EP. 2 Advantages of the molecular structure of aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 3 Treat-and-Extend Strategy With Aflibercept

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 4 Assessing New Therapies for Retinal Diseases

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 7 Patient Selection for Aflibercept 8 mg

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 8 Faricimab Molecular Design and Role of Ang-2

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 9 Outcomes with Faricimab and Choosing Between the New Therapies

EP. 10 Safety Profile of New Therapies

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 11 Perspectives on the Usefulness of Real-world Data

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

How do real-world data contribute to understanding the effectiveness of a therapy? What challenges arise when translating clinical trial results into real-world practice?

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Related Content

(Image credit: AdobeStock/Kyryl) Geographic atrophy: When lesion borders cannot be graded

Geographic atrophy: When lesion borders cannot be graded

ByModern Retina Staff

June 13th 2026

(Image credit: Modern Retina) The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS

The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS

ByChristina Y. Weng, MD, MBA, FASRS,David A. Eichenbaum, MD, FASRS

June 11th 2026

(Image credit: Modern Retina) Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments

Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments

ByArshad M. Khanani, MD, MA, FASRS,Sheryl Stevenson

June 9th 2026

Cyrus Karkaria, PhD | FDA News

FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes

ByCyrus Karkaria, PhD,Modern Retina Staff

Published: June 5th 2026 | Updated: June 11th 2026

(Image credit: AdobeStock/cirquedesprit) Phase 3 data support OTX-TKI's durability in wet AMD: 1 injection, 1 year

Phase 3 data support OTX-TKI's durability in wet AMD: 1 injection, 1 year

ByModern Retina Staff

June 1st 2026

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Trending on Modern Retina

Clinical Trials at the Summit 2026: First-time data, AI, and the next generation of retinal treatments

The Retina TL;DR with Dr. Weng: Clinical trials, career, and community with David A. Eichenbaum, MD, FASRS

Geographic atrophy: When lesion borders cannot be graded

FDA guidance to help accelerate cell and gene therapies

Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease